Idera Pharmaceuticals (NASDAQ: IDRA) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
This is a summary of recent ratings and price targets for Idera Pharmaceuticals and Momenta Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
24.1% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 93.4% of Momenta Pharmaceuticals shares are held by institutional investors. 12.4% of Idera Pharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Idera Pharmaceuticals and Momenta Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Idera Pharmaceuticals||$16.20 million||27.31||-$38.38 million||($0.34)||-6.68|
|Momenta Pharmaceuticals||$109.62 million||9.86||-$21.00 million||($0.80)||-17.69|
Momenta Pharmaceuticals has higher revenue and earnings than Idera Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Idera Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
This table compares Idera Pharmaceuticals and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Idera Pharmaceuticals beats Momenta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.